AgeX: randomising just one extra mammogram in 3 million women
With risk-appropriate regulation, UK electronic health records can facilitate large-scale studies. AgeX, the largest randomised treatment trial ever conducted, can assess realistically small effects of one extra mammographic screening invitation. Three million potentially compliant women have been randomised between invitation and control, and electronic follow-up is monitoring the effects on breast cancer incidence, treatment, and mortality.
Date: 23 January 2024, 13:00 (Tuesday, 2nd week, Hilary 2024)
Venue: Richard Doll Building, Old Road Campus OX3 7LF
Venue Details: Lecture Theatre
Speaker: Sir Professor Richard Peto
Organising department: Nuffield Department of Population Health
Part of: Richard Doll Seminars
Booking required?: Not required
Audience: Members of the University only
Editors: Graham Bagley, Hannah Calkin, Isobel Young